BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1069561)

  • 21. In vitro assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report.
    Nathanson L; Clark DA
    Natl Cancer Inst Monogr; 1973 Dec; 39():221-4. PubMed ID: 4595321
    [No Abstract]   [Full Text] [Related]  

  • 22. Active immunotherapy with B.C.G. for recurrent malignant melanoma.
    Gutterman JU; Mavligit G; McBride C; Frei E; Freireich EJ; Hersh EM
    Lancet; 1973 Jun; 1(7814):1208-12. PubMed ID: 4122562
    [No Abstract]   [Full Text] [Related]  

  • 23. In vivo delayed hypersensitivity reactions to partially purified human melanoma antigens.
    Sutherland CM; Leong SP; Cooperband SR; Deckers PJ; Hornung MO; Krementz ET
    J Surg Oncol; 1982 Aug; 20(4):221-6. PubMed ID: 7109625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCG in cancer therapy: theoretical bases of immunotherapy.
    Dodd MJ
    Am J Nurs; 1979 Feb; 79(2):310-4. PubMed ID: 311587
    [No Abstract]   [Full Text] [Related]  

  • 25. HLA-B7 associated tuberculin hyporesponsiveness in BCG treated melanoma patients.
    Buckley CE; White DH; Seigler HF
    Monogr Allergy; 1977; 11():97-105. PubMed ID: 876133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunology and the melanomas.
    Lewis MG
    Curr Top Microbiol Immunol; 1974; 63():49-84. PubMed ID: 4597749
    [No Abstract]   [Full Text] [Related]  

  • 27. [Immunological aspects of melanoma].
    Sjögren H
    Lakartidningen; 1976 Feb; 73(7):528-30. PubMed ID: 1250045
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunotherapy for melanoma.
    Vaisrub S
    JAMA; 1973 Sep; 225(10):1242. PubMed ID: 4542440
    [No Abstract]   [Full Text] [Related]  

  • 29. The survival of patients with malignant melanoma receiving BCG with or without chemotherapy.
    Green MD; MacKay IR; Buckley JC; Coates AS
    Aust N Z J Surg; 1979 Jun; 49(3):335-9. PubMed ID: 289374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignant melanoma.
    Spitler LE
    J Invest Dermatol; 1976 Sep; 67(3):435-41. PubMed ID: 787436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune response and non-specific immunotherapy in melanoma.
    El-Domeiri AA
    Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.
    Wile AG; Sparks FC; Morton DL
    Cancer Res; 1977 Jul; 37(7 Pt 1):2251-6. PubMed ID: 324610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
    Kokoschka EM; Micksche M
    Wien Klin Wochenschr; 1976 Nov; 88(21):690-6. PubMed ID: 1007279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The characterization of tumour-associated membrane-bound antigens and their implementation in the treatment of malignant melanoma (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr Suppl; 1979; 97():3-32. PubMed ID: 106559
    [No Abstract]   [Full Text] [Related]  

  • 35. Management of recurrent melanoma of the extremity.
    Shingleton WW; Seigler HF; Stocks LH; Downs RW
    Cancer; 1975 Mar; 35(3):574-9. PubMed ID: 234293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Active specific immunization in malignant melanoma.
    Gercovich FG; Gutterman JU; Mavligit GM; Hersh EM
    Med Pediatr Oncol; 1975; 1(3):277-87. PubMed ID: 1232535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future.
    Gutterman JU; Mavligit G; Reed R; Richman S; McBride CE; Hersh EM
    Semin Oncol; 1975 Jun; 2(2):155-74. PubMed ID: 790574
    [No Abstract]   [Full Text] [Related]  

  • 38. Active-specific immunotherapy for melanoma.
    Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
    J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-specific and specific active immunotherapy in a B16 murine melanoma system.
    Avent J; Vervaert C; Seigler HF
    J Surg Oncol; 1979; 12(1):87-96. PubMed ID: 480953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New approach to immunotherapy of melanoma.
    Brandes LJ; Galton DA; Wiltshaw E
    Lancet; 1971 Aug; 2(7719):293-5. PubMed ID: 4104979
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.